BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
24 Juli 2023 - 12:45PM
BioNTech to Report Second Quarter 2023 Financial Results and
Operational Update on August 7, 2023
MAINZ, Germany, July 24, 2023 (GLOBE
NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the
Company”) will announce its financial results for the second
quarter 2023 on Monday, August 7th, 2023. BioNTech invites
investors and the general public to join a conference call and
webcast with investment analysts on the same day at 8.00 a.m. EDT
(2.00 p.m. CEST) to report its financial results and provide a
corporate update for the second quarter 2023.
To access the live conference call via
telephone, please register via this link. Once registered, dial-in
numbers and a pin will be provided. It is recommended to register
at least a day in advance.
The slide presentation and audio of the webcast
will be available via this link.
Participants may also access the slides and the
webcast of the conference call via the “Events & Presentations”
page of the Investor Relations section of the Company’s website at
www.BioNTech.com. A replay of the webcast will be available shortly
after the conclusion of the call and archived on the Company’s
website for 30 days following the call.
About BioNTechBiopharmaceutical New
Technologies (BioNTech) is a next generation immunotherapy company
pioneering novel therapies for cancer and other serious diseases.
The Company exploits a wide array of computational discovery and
therapeutic drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor T cells, bispecific
immune checkpoint modulators, targeted cancer antibodies and small
molecules. Based on its deep expertise in mRNA vaccine development
and in-house manufacturing capabilities, BioNTech and its
collaborators are developing multiple mRNA vaccine candidates for a
range of infectious diseases alongside its diverse oncology
pipeline. BioNTech has established a broad set of relationships
with multiple global pharmaceutical collaborators, including
DualityBio, Fosun Pharma, Genentech, a member of the Roche Group,
Genevant, Genmab, OncoC4, Regeneron, Sanofi, and Pfizer.
For more information, please visit
www.BioNTech.com.
BioNTech Contacts
Investor RelationsVictoria Meissner,
M.D.+1 617 528 8293Investors@biontech.de
Media RelationsJasmina Alatovic+49
(0)6131 9084 1513Media@biontech.de
Biontech (LSE:0A3M)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Biontech (LSE:0A3M)
Historical Stock Chart
Von Mai 2023 bis Mai 2024